Avacta Group (AVCT)
AVCT Share PerformanceMore
|52 week high||98.00 26/05/17|
|52 week low||60.00 31/03/17|
|52 week change||-6.50 (-8.90%)|
|4 week volume||295,899 25/12/17|
Media for (AVCT)
Latest News« previous» nextMore
18/01/2018 - 07:31 StockMarketWire
Avacta expects revenue, operating losses and cash balances for the six months ending 31 Jan to be in line with market forec...
15/01/2018 - 10:58 RNS
RNS Number: 8785B Avacta Group PLC 15 January 2018 Hardman Research: Affimer Drug Conjugates a reality Affimer Drug Conjugates a reality - Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which...
15/01/2018 - 07:04 StockMarketWire
Avacta Group and Glythera have agreed the terms of a licensing deal which will allow them to develop drug conjugates u...
15/01/2018 - 07:00 RNS
RNS Number: 7915B Avacta Group PLC 15 January 2018 15 January 2018 Avacta Group plc ("Avacta" or "the Group" or "the Company") Positive Outcome of Proof-of-Concept Study with Glythera and Follow on Drug Development Partnership Successful proof-of-concept study leads to Affimer drug conjugate development partnership Affimers shown to have key ...
08/01/2018 - 09:26 StockMarketWire
Avacta Group will host a capital markets day for financial analysts and institutional investors at finnCap's offices, 60 New...
08/01/2018 - 07:00 RNS
RNS Number: 7710A Avacta Group PLC 08 January 2018 8 January 2018 Avacta Group plc ("Avacta", "the Group" or "the Company") Capital Markets Day Notification Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, today announces that it will host a Capital Markets Day for financial analysts and institutional investors on W...
04/01/2018 - 11:04 RNS
RNS Number: 9751A Avacta Group PLC 04 January 2018 4 January 2018 Avacta Group plc ("Avacta", "the Group" or "the Company") Issue of Equity Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, announces that application has been made for 5,805 new ordinary shares of 10p each (the "New Ordinary Shares") to b...
03/01/2018 - 07:38 StockMarketWire
Avacta Group chief executive Dr Alastair Smith will be presenting at the annual Biotech Showcase which is being held in ...
|Dividend yield||0 %|
Latest discussion posts More
“Do you really see Avacta as being a #2 billion company?”▼
“albeit back in sept 17 - article by amrik Guest Commentary: Affinity and beyond--Assessing the alternatives to therapeutic ...”▼
“Current significant shareholders are as follows IP Group plc ? 24.79% Lombard Odier Asset Management ? 10.77% Aviva 9.60% Ruffer LLP ? 7.08% J O Hambro - 6.72% Baillie ...”▼
Codes & Symbols
|Symbols||AVCT, LSE:AVCT, AVCT.L, AVCT:LN, LON:AVCT, XLON:AVCT|
Join interactive investor
- £22.50 fixed quarterly charge includes £22.50 in trading credits
- £10 per trade or £6 for frequent traders
- No % platform fees
- £1 per trade for regular investment or dividend reinvestment